[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma
This will be a pivotal prospective prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial to assess the diagnostic performance and safety of the positron emission tomography (PET) imaging agent \[68Ga\]Ga-PTF) , versus \[18F\]FDG PET/CT imaging, for staging of patients with confirmed marginal zone lymphoma exemplary for CXCR4-positive malignant lymphomas.
Marginal Zone Lymphoma
DRUG: [68Ga]Ga-PentixaFor|DRUG: [18F]Fluorodeoxyglucose
Sensitivity of [68Ga]Ga-PTF PET/CT imaging vs. [18F]FDG PET/CT imaging in tumor detection, Through study completion, an average of 6 months|Specificity of [68Ga]Ga-PTF PET/CT imaging vs. [18F]FDG PET/CT imaging in tumor detection, Through study completion, an average of 6 months
Proportion of patients with additional or less lesions detected by each PET/CT imaging agent ([68Ga]Ga-PTF and [18F]FDG) compared to pre-PET conventional staging as assessed by questionnaires completed by the referring physicians, Through study completion, an average of 6 months|Proportion of patients with a change in intended patient management due to additional or less lesions detected by each PET/CT imaging agent ([68Ga]Ga-PTF and [18F]FDG) as assessed by questionnaires completed by the referring physicians, Through study completion, an average of 6 months|Proportion of patients with additional or less lesions detected by each PET/CT imaging agent ([68Ga]Ga-PTF and [18F]FDG) compared to pre-PET conventional staging as assessed by questionnaires completed by an Independent Committee, Through study completion, an average of 6 months|Inter-observer agreement of local and central assessment in terms of staging, Through study completion, an average of 6 months|Proportion of patients with nodal MZL with additional or less lesions detected by each PET/CT imaging agent ([68Ga]Ga-PTF and [18F]FDG) compared to pre-PET conventional staging as assessed by questionnaires completed by the referring physicians, Through study completion, an average of 6 months|Proportion of patients with extranodal MZL with additional or less lesions detected by each PET/CT imaging agent ([68Ga]Ga-PTF and [18F]FDG) compared to pre-PET conventional staging as assessed by questionnaires completed by the referring physicians, Through study completion, an average of 6 months|Proportion of patients with splenic MZL with additional or less lesions detected by each PET/CT imaging agent ([68Ga]Ga-PTF and [18F]FDG) compared to pre-PET conventional staging as assessed by questionnaires completed by the referring physicians, Through study completion, an average of 6 months|Proportion of patients with nodal MZL with a change in intended patient management due to additional or less lesions detected by each PET/CT imaging agent ([68Ga]Ga-PTF and [18F]FDG) as assessed by questionnaires completed by the referring physicians, Through study completion, an average of 6 months|Proportion of patients with extranodal MZL with a change in intended patient management due to additional or less lesions detected by each PET/CT imaging agent ([68Ga]Ga-PTF;[18F]FDG) as assessed by questionnaires completed by the referring physicians, Through study completion, an average of 6 months|Proportion of patients with splenic MZL with a change in intended patient management due to additional or less lesions detected by each PET/CT imaging agent ([68Ga]Ga-PTF and [18F]FDG) as assessed by questionnaires completed by the referring physicians, Through study completion, an average of 6 months|Diagnostic performance, consisting of sensitivity and specificity, of each PET/CT imaging agent in tumor detection on a region-basis (eyes, ears, nose, throat, liver, spleen, gastrointestinal tract, bone marrow) confirmed by SoT or surrogate SoT, Through study completion, an average of 6 months|Sensitivity of each PET/CT imaging agent in tumor detection on a patient-basis confirmed by SoT or surrogate SoT, Through study completion, an average of 6 months|Positive and negative predictive values (PPV, NPV) of each PET/CT imaging agent to detect tumor on a patient-basis and lesion-basis, Through study completion, an average of 6 months|Detection rate of each PET/CT imaging agent to detect tumor on a patient-basis and lesion-basis confirmed by SoT or surrogate SoT, Through study completion, an average of 6 months|Proportion of patients with additional or less tumoral lesions detected by [68Ga]Ga-PTF PET/CT imaging compared to [18F]FDG PET/CT imaging, Through study completion, an average of 6 months|Inter-reader and intra-reader agreement for tumor detection of each PET/CT imaging agent on a lesion-basis and patient-basis, Through study completion, an average of 6 months|Reproducibility of [68Ga]Ga-PTF PET/CT imaging (reproducibility group), Through study completion, an average of 6 months|Maximum standardized uptake value (SUVmax), SUVpeak and SUV mean of each PET/CT imaging agent, Through study completion, an average of 6 months|Target-to-background ratio (TBR) of each PET/CT imaging agent, Through study completion, an average of 6 months|Contrast-to-noise ratio (CNR) of each PET/CT imaging agent, Through study completion, an average of 6 months|Signal-to-noise ratio (CNR) of each PET/CT imaging agent, Through study completion, an average of 6 months|Frequency and Severity of Adverse Events for each PET/CT imaging agent, Prior injection of each PET/CT imaging agent and after injection of each PET/CT imaging agent|Frequency and kind of adverse effects present at the injection site, The safety and tolerability for each PET/CT imaging agent will be evaluated by the assessment of the injection site status (which kind of adverse effects have appeared) after the injection of each PET/CT imaging compound, 2-3 hours after injection of each PET/CT imaging agent|Clinical significance of abnormal results during physical examination, The safety and tolerability for each PET/CT imaging agent will be evaluated by the assessment of physical examination findings, Prior injection of each PET/CT imaging agent and after injection of each PET/CT imaging agent|Blood pressure (systolic and diastolic), The safety and tolerability for each PET/CT imaging agent will be evaluated by the assessment of blood pressure (systolic and diastolic), Prior injection of each PET/CT imaging agent and after injection of each PET/CT imaging agent|Heart or pulse rate, The safety and tolerability for each PET/CT imaging agent will be evaluated by the assessment of heart or pulse rate, Prior injection of each PET/CT imaging agent and after injection of each PET/CT imaging agent|RR interval findings/abnormalities, The safety and tolerability for each PET/CT imaging agent will be evaluated by the assessment of findings/abnormalities in the RR interval, Prior injection of each PET/CT imaging agent and after injection of each PET/CT imaging agent|PQ interval findings/abnormalities, The safety and tolerability for each PET/CT imaging agent will be evaluated by the assessment of PQ interval findings/abnormalities, Prior injection of each PET/CT imaging agent and after injection of each PET/CT imaging agent|QRS complex findings/abnormalities, The safety and tolerability for each PET/CT imaging agent will be evaluated by the assessment of QRS complex findings/abnormalities, Prior injection of each PET/CT imaging agent and after injection of each PET/CT imaging agent|QT interval findings/abnormalities, The safety and tolerability for each PET/CT imaging agent will be evaluated by the assessment of QT interval findings/abnormalities, Prior injection of each PET/CT imaging agent and after injection of each PET/CT imaging agent|QTc interval findings/abnormalities, The safety and tolerability for each PET/CT imaging agent will be evaluated by the assessment of QTc interval findings/abnormalities, Prior injection of each PET/CT imaging agent and after injection of each PET/CT imaging agent|Weight, The safety and tolerability for each PET/CT imaging agent will be evaluated by the assessment of patient weight, Prior injection of each PET/CT imaging agent and after injection of each PET/CT imaging agent
Sensitivity of [68Ga]Ga-PTF PET/CT imaging in detecting CXCR4 overexpressing tissue confirmed by a CXCR4 SoT (CXCR4 IHC), Sensitivity of \[68Ga\]Ga-PTF PET/CT imaging in detecting CXCR4 overexpressing tissue will be analyzed on a lesion-basis and will be confirmed by a CXCR4 SoT (CXCR4 IHC), Through study completion, an average of 6 months|Specificity of [68Ga]Ga-PTF PET/CT imaging in detecting CXCR4 overexpressing tissue, Specificity of \[68Ga\]Ga-PTF PET/CT imaging in detecting CXCR4 overexpressing tissue will be analyzed on a lesion-basis and will be confirmed by a CXCR4 SoT (CXCR4 IHC), Through study completion, an average of 6 months|Receiver-operating-characteristic (ROC) curve analysis, Through study completion, an average of 6 months|Determination of the area under the curve (AUC), Through study completion, an average of 6 months|Correlation of [68Ga]Ga-PTF uptake in PET and CXCR4 overexpression by IHC, Through study completion, an average of 6 months|Correlation of the Ki-67 proliferation index with CXCR4 overexpression and with SUVmean on a lesion-basis, Through study completion, an average of 6 months|Correlation of the Ki-67 proliferation index with CXCR4 overexpression and with SUVmax on a lesion-basis, Through study completion, an average of 6 months|Rate of non-tumoral CXCR4-positive and CXCR4-negative lesions found in the [68Ga]Ga-PTF PET/CT imaging, Through study completion, an average of 6 months|Percentage of patients with within-patient discordant lesions in terms of CXCR4 expression, Through study completion, an average of 6 months|Positive predictive value (PPV) of [68Ga]Ga-PTF PET/CT imaging for detection of CXCR4 overexpressing tissue, Through study completion, an average of 6 months|Negative predictive value (NPV) of [68Ga]Ga-PTF PET/CT imaging for detection of CXCR4 overexpressing tissue, Through study completion, an average of 6 months
This will be a pivotal prospective prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial to assess the diagnostic performance and safety of the positron emission tomography (PET) imaging agent \[68Ga\]Ga-PTF) , versus \[18F\]FDG PET/CT imaging, for staging of patients with confirmed marginal zone lymphoma exemplary for CXCR4-positive malignant lymphomas.